Core Viewpoint - The recent trend of new economy companies, particularly in the fields of autonomous driving and biotechnology, is leading to a wave of dual listings in Hong Kong following the successful dual listing of Hesai Technology on September 16 [1] Group 1: Company Developments - Tianjing Bio announced its plan to return to Hong Kong for a dual primary listing on October 17 [1] - In the intelligent driving sector, WeRide and Pony.ai have initiated the Hong Kong listing process after receiving approval from the China Securities Regulatory Commission for overseas listings [1] - Pony.ai has already passed the listing hearing with the Hong Kong Stock Exchange [1] Group 2: Market Implications - The return of technology-intensive new economy companies is expected to enhance the ecosystem of the Hong Kong stock market [1]

天眼查App显示，近日，朔益（丹阳）生物科技有限公司成立，法定代表人为王国民，注册资本100万 人民币，经营范围为许可项目：食品生产；保健食品生产；食品添加剂生产；饮料生产；化妆品生产； 消毒剂生产（不含危险化学品）；卫生用品和一次性使用医疗用品生产（依法须经批准的项目，经相关 部门批准后方可开展经营活动，具体经营项目以审批结果为准）一般项目：食品销售（仅销售预包装食 品）；保健食品（预包装）销售；宠物食品及用品批发；宠物食品及用品零售；食品添加剂销售；食品 互联网销售（仅销售预包装食品）；食品进出口；包装服务；技术服务、技术开发、技术咨询、技术交 流、技术转让、技术推广；技术推广服务；货物进出口；生物化工产品技术研发；发酵过程优化技术研 发；卫生用品和一次性使用医疗用品销售；第二类医疗器械销售；消毒剂销售（不含危险化学品）；远 程健康管理服务；健康咨询服务（不含诊疗服务）（除依法须经批准的项目外，凭营业执照依法自主开 展经营活动）。 ...

天眼查App显示，近日，上海谷钛生物科技有限公司成立，法定代表人为刘皓哲，注册资本100万人民 币，经营范围为一般项目：技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广；化妆品 批发；化妆品零售；日用品批发；日用品销售；日用化学产品制造；日用化学产品销售；化工产品销售 （不含许可类化工产品）；日用百货销售；日用杂品销售；塑料制品销售；厨具卫具及日用杂品批发； 厨具卫具及日用杂品零售；针纺织品及原料销售；针纺织品销售；个人卫生用品销售；卫生用品和一次 性使用医疗用品销售；电子产品销售；母婴用品销售；玩具销售；户外用品销售；文具用品批发；文具 用品零售；办公用品销售；家用电器销售；日用家电零售；互联网销售（除销售需要许可的商品）；货 物进出口；技术进出口。（除依法须经批准的项目外，凭营业执照依法自主开展经营活动）。 ...

Core Insights - The article discusses the development of an AI-driven digital cloning selection platform (Digital Colony Picker, DCP) for high-throughput single-cell screening, which addresses the challenges in microbial strain selection and industrial application [2][4]. Group 1: Technology Development - The DCP system utilizes three major technological innovations: micro-chamber separation culture, AI-assisted image recognition, and non-contact laser single-clone picking, enabling precise high-throughput screening of microbial multi-dimensional phenotypes [4][5]. - The DCP platform can independently culture individual microbial cells using a microfluidic chip with thousands of micro-chambers, allowing real-time monitoring of cell growth dynamics, metabolic activity, and morphological characteristics [5][6]. Group 2: Application and Results - In application validation, researchers successfully isolated a "super strain" of Zymomonas mobilis, which showed a 19.6% increase in lactic acid production and a 75.9% improvement in growth rate under 30 g/L lactic acid stress conditions [5]. - The superior phenotype of the isolated strain is linked to mutations and overexpression of the outer membrane transporter gene ZMOp39x027, enhancing lactic acid transmembrane transport capacity [5]. Group 3: Future Prospects - The DCP platform is expected to significantly accelerate the discovery of superior strains, providing strong technical support for metabolic engineering, environmental microbial resource exploration, and industrial strain optimization [5]. - The DCP platform works synergistically with the FlowRACS system, which excels in instantaneous snapshot/sorting capabilities, creating a comprehensive solution for functional strain discovery [6].

以下文章来源于南风窗 ，作者乔悦 南风窗 . 冷静地思考，热情地生活。 我们究竟准备好了怎样的开放？ 我们如何引领未来？ 文 ｜ 乔悦 编辑 ｜ 何承波 来源｜ 南风窗（ID：SouthReviews） 封面来源 ｜ IC photo 原本只是一次没有引起关注的签证政策调整，却突然在近2个月后，引爆了社交媒体。 9月底，网上出现大量短视频，标题大多是"印度人盯上K签证""外国人要来抢中国人的饭碗"等，视频配着急促的音乐与醒目的字幕，评论区的疑问此起彼 伏："国内理工科毕业生都找不到工作了，国家还要把门打开给外国人？" 类似的争论接连出现，成了国庆期间的热搜话题。一些AI视频里，长着南亚长相的人，在拥挤的高铁站排起了长队，正等着领取K签入境。一时间，"印 度人偷家"的说辞，在各路自媒体和网友口中传开。 让舆论沸腾的，是国务院新增的一项K类签证。 8月7日，《国务院关于修改〈中华人民共和国外国人入境出境管理条例〉的决定》公布，关于K签的内容很简短："发给入境的外国青年科技人才"，10月 1日起正式实施。 签证的类别和签发节选 / 图源： 中华人民共和国外国人入境出境管理条例 记者会上，相关部门解释称，K签面向从境 ...

当全球经济格局深度调整，香港作为联结世界的战略枢纽，成为企业家把握新机遇的关键锚点。 清华五道口 首个布局香港与全球化的旗舰课程 "紫荆计划"项目 正以清晰的确定性与卓越价值 迎来开班倒计时 1 2月4日开学日期已定！ 集结的同学均为各领域顶尖力量：既有上市公司核心决策者，也有AI、生物科技赛道的领军者，以 及深耕跨境支付、数字资产的先行者，覆盖资本市场、科技创新、全球化布局等关键领域。 作为依托清华五道口顶尖学术资源与香港政商核心网络打造的课程，"紫荆计划"以"系统讲授+深度 对谈+实地探访"三维体系为基石：带你直通香港特区政府机构、联交所、金管局等核心平台，在联 席学术顾问李剑阁、梁定邦等国家智囊的带领下，从理解香港社会文化、融入本地商业生态，到洞 悉AI与Web3变革、布局亚太及"一带一路"机遇，每一环均指向"融入香港、走向世界"的实战价值。 如果你是有志以香港为支点拓展全球版图的企业决策者，若您渴望与优质同窗并肩，在再全球化浪 潮中抢占先机，在顶尖高校赋能下打通香港资源脉络、实现企业跨越发展，欢迎加入"紫荆计划"， 共赴这场扎根香港、走向世界的进阶之旅！ 0985 JIII PROGRAM 融入香港商 ...

天眼查App显示，近日，广州橙汁生物科技有限公司成立，注册资本3万人民币，经营范围为化妆品批 发;互联网销售（除销售需要许可的商品）;技术服务、技术开发、技术咨询、技术交流、技术转让、技 术推广;日用品批发;计算机软硬件及辅助设备批发;五金产品批发;工艺美术品及收藏品批发（象牙及其 制品除外）;珠宝首饰批发;体育用品及器材批发;文具用品批发;鞋帽批发;服装服饰批发;卫生洁具销售;玩 具、动漫及游艺用品销售;户外用品销售;箱包销售;日用品销售;个人卫生用品销售;家居用品销售;销售代 理;人工智能硬件销售;家用电器销售;化妆品零售。 ...

Core Viewpoint - Hong Kong Futures Exchange plans to launch futures contracts based on the Hang Seng Biotechnology Index on November 28, 2025, pending regulatory approval [1] Group 1: Futures Contract Details - The futures contract will be based on the Hang Seng Biotechnology Index, which tracks the 30 largest biotechnology companies listed in Hong Kong [1] - The contract code will be HBI, with each index point valued at 50 HKD, resulting in a contract value of approximately 776,000 HKD based on the closing price on October 14, 2025 [3] - The contract will have monthly, quarterly, and subsequent quarterly expirations, with cash settlement in HKD [3] Group 2: ETF Performance and Characteristics - The Hang Seng Biotechnology ETF (513280) has a management fee of 0.15% per year and has seen a significant net inflow of funds, with a year-to-date share growth rate of 24% [1][4] - The ETF's underlying index has a high concentration in innovative drugs (69%) and CXO (over 20%), providing exposure to high-growth sectors [4][6] - The index has shown a remarkable return of 79.67% over the past year, with the ETF outperforming the index with a return of 80.9% [6][10] Group 3: Market Context and Trends - The introduction of the Hang Seng Biotechnology Index futures reflects the growing importance of the biotechnology sector, paralleling the Hang Seng Technology Index [2] - The biotechnology sector is described as the fastest-growing and most dynamic segment in the market, indicating strong investor interest and potential for future growth [1][2] - Analysts are optimistic about the long-term trends in innovative drugs and the overall health of Hong Kong's pharmaceutical companies, supported by stable cash flows and robust R&D pipelines [9]

Core Insights - The 2025 Nobel Prize in Physiology or Medicine was awarded to three scientists for groundbreaking discoveries in regulatory T cells, revealing how the immune system maintains self-balance through "peripheral immune tolerance," which is crucial for understanding autoimmune diseases and developing new cancer immunotherapy strategies [4][5] - Traditional animal models struggle to accurately simulate the human immune system due to species differences, leading to challenges in mechanism research, clinical translation, and model construction [4] - Humanized immune system mice provide a key technology to address these issues, allowing for effective preclinical evaluation of candidate drugs, significantly reducing subsequent development risks, and providing a reliable platform for assessing new cell therapies and bispecific antibodies [5] Course Overview - An online course titled "Applications of Humanized Immune System Mice in Tumor Immunity and Autoimmune Diseases" will be held on October 21, featuring Dr. Yu Jing, a senior scientist at Saiye Bio, focusing on scientific decision-making for obtaining valuable experimental data [5][7] - The course will cover the following topics: 1. Advances in tumor immunity: Translating Nobel-level discoveries into new treatment strategies and related research dynamics [7] 2. Model development history: Reviewing the evolution of models and the characteristics and applicable scenarios of PBMC, HSC, and other construction strategies [7] 3. Optimization strategies and application cases: Emphasizing research on tumor immunity and autoimmune diseases, drug efficacy, and safety evaluation [7] 4. Interactive session: The lecturer will answer common questions related to disease research [7] Research Applications - The huHSC-C-NKG-ProF model has been utilized in significant research, including: 1. CAR-T cell therapy for solid tumors, revealing how Foxp3 regulates CAR-T cell metabolism to enhance treatment efficacy [12] 2. Liver cancer immune evasion studies, identifying ETV5 as a potential biomarker for prognosis and a target for new treatment strategies [12] - Saiye Bio's humanized immune system mice, particularly the huHSC-C-NKG-ProF model, can reconstruct various human immune cells, providing a robust platform for research [13][14] Product Offerings - Saiye Bio offers several humanized immune system models, including: - huHSC-C-NKG-ProF: Full immune system reconstruction with a humanization rate of 40-60% after 8 weeks [16] - huHSC-C-NKG-ProM: Reconstructs lymphoid T and B cells with a similar humanization rate [16] - huHSC-C-NKG-ProN: Focuses on T, B, and NK cells with minimal myeloid development [16] - huHSC-C-NKG: Supports long-term presence of human cells with a lifespan exceeding one year [16] - huPBMC-C-NKG: Primarily reconstructs lymphoid T cells with a fast reconstruction speed [16]

撰文丨王聪 编辑丨王多鱼 排版丨水成文 在生命科学领域，设计一个能够精确响应环境信号的蛋白质，一直是科学家们的梦想。特别是对于跨越细胞膜的蛋白质——它们控制着细胞与外界的信息交流， 如同城市的门户和关卡。 尽管科学家们已经取得了一些进展，例如设计出稳定的膜蛋白支架和跨膜孔道，但要从头开始设计一个能够响应特定刺激 （例如电压变化） 并通过构象变化来控 制离子流动的跨膜蛋白，仍然是一个巨大挑战。 2025 年 10 月 16 日， 西湖大学生命科学学院、西湖实验室及遗传物质表达与重构全国重点实验室 卢培龙 团队，联合西湖实验室/西湖大学 李波 、 黄晶 等 团 队，在国际顶尖学术期刊 Cell 上 发表题为： De novo designed voltage-gated anion channels suppress neuron firing 的研究论文。 该研究 首次从头设计出了 电压门控阴离子通道 —— dVGAC ，这些通道不仅具有独特的结构和工作机制，还能够 在小鼠模型中有效抑制神经元电活动 。 该研究不仅表明科学家已具备 从头设计具有 " 动态开关 " 功能的跨膜蛋白 的能力，更证明此类人工蛋白可在活 ...